Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained a $10 price target.
June 19, 2024 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100